- Synthesized numerous novel small molecule target compounds and further characterized the properties and pharmacological activity of many of those compounds. Designed and conducted synthesis of carbohydrate derivatives under a federal grant for use as tissue preservatives in organ harvesting and transplant.
- Represented Advaxis Inc., a biopharmaceutical company developing immunotherapies, in a clinical collaboration and licensing deal with Amgen Inc. for a preclinical candidate involving $65 million in upfront cash and equity investment with $475 million in development, regulatory and sales milestones and tiered royalties on net sales.
- During reexamination proceedings, defended four patents that cover a client’s pharmaceutical products, representing over $1 billion in sales annually.
- Conducted due diligence investigations for pharmaceutical clients seeking to acquire early- and late-stage drug candidates.
- Managed an emerging pharmaceutical company’s patent estate covering a small molecule drug candidate (now in clinical trials) and assisted in due diligence that attracted multimillion-dollar funding for the company.
- Developed patent strategies for international patent portfolios covering a range of technologies for large multinational corporations, startup pharmaceutical companies and biotech companies.
- Worked with in-house counsel and university technology transfer personnel on contract issues, including research collaboration and licensing agreements.
Partner,
- Phone: +1 919 862 2241
- Email: bryan.skelton@alston.com
Bryan's clients rely on his years of experience in intellectual property counseling and his focus on developing, executing and enforcing worldwide market exclusivity strategies for their core assets. Pharmaceutical, chemical and biotechnology companies of all sizes call on Bryan for portfolio growth, management and acquisition, due diligences and strategic partnering.
Bryan Skelton focuses his practice on advising pharmaceutical companies and research institutions on complex legal issues relating to the protection, enforcement and transfer of intellectual property. He has extensive experience in technologies directed to small molecule compounds, compositions and their delivery, and immunology, particularly vaccines and antibodies. His services include counseling clients on developing and implementing patent procurement and reexamination strategies, assisting clients with intellectual property valuations and licensing, conducting due diligence investigations of patent portfolios and preparing opinions on validity, noninfringement and freedom to operate. A significant portion of Bryan’s practice involves conducting due diligence investigations for clients in connection with acquisitions or investment funding. He also advises pharmaceutical and life sciences companies in various IP Litigation matters.
Bryan’s doctoral research in medicinal chemistry focused on designing and synthesizing novel nicotine-based molecules as ligands for nicotinic acetylcholine receptors, which have been implicated in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
His technical background provides a deep understanding of complex organic syntheses. He has extensive patent procurement experience in the areas of small molecules, polymers and composite materials.
-
Press Release June 11, 2024Alston & Bird Earns Broad Recognition in 2024 IAM Patent 1000For the thirteenth consecutive year, Alston & Bird has been recognized as a global leader in patent law by Intellectual Asset Management in its annual IAM Patent 1000 – The World’s Leading Patent Professionals.Press Release June 11, 2024Alston & Bird Earns Broad Recognition in 2024 IAM Patent 1000For the thirteenth consecutive year, Alston & Bird has been recognized as a global leader in patent law by Intellectual Asset Management in its annual IAM Patent 1000 – The World’s Leading Patent Professionals.
-
Press Release June 28, 2023Alston & Bird Earns Broad Recognition in 2023 IAM Patent 1000For the twelfth consecutive year, Alston & Bird has been recognized as a global leader in patent law by Intellectual Asset Management in its annual IAM Patent 1000 – The World’s Leading Patent Professionals.Press Release June 28, 2023Alston & Bird Earns Broad Recognition in 2023 IAM Patent 1000For the twelfth consecutive year, Alston & Bird has been recognized as a global leader in patent law by Intellectual Asset Management in its annual IAM Patent 1000 – The World’s Leading Patent Professionals.
-
Advisories January 17, 2023Intellectual Property Advisory: New Initiatives Benefiting Small Businesses at the U.S. Patent and Trademark OfficeOur Intellectual Property Group reviews how a summer rule change from the Small Business Administration dovetails with the newly enacted Unleashing American Innovators Act.Advisories January 17, 2023Intellectual Property Advisory: New Initiatives Benefiting Small Businesses at the U.S. Patent and Trademark OfficeOur Intellectual Property Group reviews how a summer rule change from the Small Business Administration dovetails with the newly enacted Unleashing American Innovators Act.
-
Press Release July 12, 2022Alston & Bird Earns Broad Recognition in 2022 IAM Patent 1000For the eleventh consecutive year, Alston & Bird has been recognized as a global leader in patent law by Intellectual Asset Management in its annual IAM Patent 1000 – The World’s Leading Patent Professionals.Press Release July 12, 2022Alston & Bird Earns Broad Recognition in 2022 IAM Patent 1000For the eleventh consecutive year, Alston & Bird has been recognized as a global leader in patent law by Intellectual Asset Management in its annual IAM Patent 1000 – The World’s Leading Patent Professionals.
-
Seminar June 8, 2022Alston & Bird Raleigh Ethics SeminarMatt McGuire will be joined by Mike Kaeding, Bryan Skelton, and Kelsey Kingsbery, along with panelists from Accord Healthcare and Truist to discuss a variety of personal and ethical liability issues that corporate counsel encounter on a daily basis.Seminar June 8, 2022Alston & Bird Raleigh Ethics SeminarMatt McGuire will be joined by Mike Kaeding, Bryan Skelton, and Kelsey Kingsbery, along with panelists from Accord Healthcare and Truist to discuss a variety of personal and ethical liability issues that corporate counsel encounter on a daily basis.
-
In the News February 3, 2021Global Legal Chronicle | OncoSec Medical’s $42 Million Shares OfferingMatt Mamak, Robyn Downing, Laura Giambalvo, Bryan Skelton, and Kirk Ekena are noted for representing OncoSec Medical Incorporated in a $42 million public offering of common stock.In the News February 3, 2021Global Legal Chronicle | OncoSec Medical’s $42 Million Shares OfferingMatt Mamak, Robyn Downing, Laura Giambalvo, Bryan Skelton, and Kirk Ekena are noted for representing OncoSec Medical Incorporated in a $42 million public offering of common stock.
-
Press Release February 1, 2021OncoSec Medical Closes $42 Million Public Offering of Common StockAlston & Bird client OncoSec Medical Incorporated, a late-stage biotechnology company, has closed a public offering of common stock that raised approximately $42 million.Press Release February 1, 2021OncoSec Medical Closes $42 Million Public Offering of Common StockAlston & Bird client OncoSec Medical Incorporated, a late-stage biotechnology company, has closed a public offering of common stock that raised approximately $42 million.
Bar Admissions
- North Carolina
- Maryland
- U.S. Patent and Trademark Office
Education
- The George Washington University (J.D., 2006)
- University of Georgia (Ph.D., 2000)
- University of West Georgia (B.A., 1992)